宜宾天原集团股份有限公司(以下简称"公司")于近日收到东方 证券股份有限公司(以下简称"东方证券")发来的《关于更换宜宾天 原集团股份有限公司 2022 年非公开发行股票并上市项目持续督导保 荐代表人的情况说明》。现将有关情况公告如下: 东方证券作为公司向特定对象发行股票并在主板上市项目的保 荐机构和持续督导机构，原委派保荐代表人郑雷钢和胡平具体负责公 司的保荐及持续督导工作，法定持续督导期限至 2024 年 12 月 31 日 止，因公司本次发行募集资金尚未使用完毕，东方证券将继续对公司 本次发行募集资金的存放和使用情况履行持续督导责任，直至募集资 金使用完毕。 目前，胡平先生因工作变动原因，不再继续担任公司持续督导保 荐代表人。为确保持续督导工作的有序进行，东方证券另行委派谭健 先生(简历详见附件)接替胡平先生担任公司持续督导工作的保荐代 表人，继续履行持续督导职责。 本次变更后，负责公司持续督导的保荐代表人为郑雷钢先生和谭 健先生。本次保荐代表人变更不会影响东方证券对公司的持续督导工 作，亦不会对公司的生产经营活动产生不利影响。 | 证券代码：002386 | 证券简称：天原股份 | 公告编号：2025 ...

暗盘资金一眼洞悉庄家意图>> 钛白粉概念板块短线拉升，安纳达（002136）涨停，惠云钛业（300891）、金浦钛业（000545）、中核 钛白（002145）、国城矿业（000688）、天原股份（002386）等纷纷走高。 ...

2、本次股东大会不涉及变更前次股东大会决议。 一、会议的召开情况 证券代码：002386 证券简称：天原股份 公告编号：2025-038 债券代码:524174.SZ 债券简称：25 天原 K1 宜宾天原集团股份有限公司 2024 年年度股东大会决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无增加、否决或变更提案的情况。 1、会议召开时间： （1）现场会议：2025 年 5 月 16 日（星期五）14:00 （2）网络投票：2025 年 5 月 16 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间 为：2025 年 5 月 16 日上午 9:15—9:25,9:30—11:30 和下午 13:00 —15:00；通过深圳证券交易所互联网投票系统投票的具体时间为： 2025 年 5 月 16 日 9:15-15:00 期间的任意时间。 2、现场会议召开地点：四川宜宾临港经济技术开发区港园路西 段 61 号公司会议室。 3、召开方式：现场投票和网络投票相结合 4、召集人：公司董事会 5、股权登记日：2025 年 ...

北京市天元（成都）律师事务所 关于宜宾天原集团股份有限公司 2024 年年度股东大会的法律意见 （2025）天（蓉）意字第 28 号 致：宜宾天原集团股份有限公司 宜宾天原集团股份有限公司（以下简称"公司"）2024 年年度股东大会（以下 简称"本次股东大会"）采取现场投票与网络投票相结合的方式，现场会议于 2025 年 5 月 16 日（星期五）下午 14:00 在四川宜宾临港经济技术开发区港园路西段 61 号宜宾天原集团股份有限公司会议室召开。北京市天元（成都）律师事务所（以下 简称"本所"）接受公司聘任，指派本所律师参加本次股东大会现场会议，并根据 《中华人民共和国公司法》《中华人民共和国证券法》（以下简称"《证券法》"）《上 市公司股东会规则》（以下简称"《股东会规则》"）以及《宜宾天原集团股份有限公 司章程》（以下简称"《公司章程》"）等有关规定，就本次股东大会的召集、召开程 序、出席现场会议人员的资格、召集人资格、会议表决程序及表决结果等事项出具 本法律意见。 为出具本法律意见，本所律师审查了《宜宾天原集团股份有限公司第九届董事 会第十四次会议决议公告》《宜宾天原集团股份有限公司第九届监事会第九次 ...

Core Viewpoint - Yibin Tianyuan Group Co., Ltd. (the company) announced a share buyback plan by its controlling shareholder, Yibin Development Holding Group Co., Ltd., with a planned investment between RMB 150 million and RMB 300 million [1][2]. Basic Information - The buyback plan was disclosed on February 11, 2025, with a six-month timeframe for execution [1]. - As of May 9, 2025, Yibin Development has cumulatively increased its shareholding through centralized bidding on the Shenzhen Stock Exchange [2]. Buyback Plan Details - The buyback plan aims to enhance investor confidence and stabilize the capital market [2]. - Yibin Development will gradually implement the buyback based on stock price fluctuations and overall market trends, adhering to legal and regulatory requirements [2][3]. Progress of Buyback Plan - By May 9, 2025, Yibin Development had acquired a total of 8,150,420 shares, increasing its ownership from 228,708,436 shares (17.57% of total shares) to 236,858,856 shares (18.20% of total shares) [3]. - The total shares held by Yibin Development and its concerted actions increased from 314,668,320 shares (24.17%) to 322,818,740 shares (24.80%) [3]. Other Relevant Information - The buyback plan is not expected to affect the company's listing status or change the actual controller [4]. - The company will continue to monitor the situation and fulfill its information disclosure obligations [4].

证券代码：002386 证券简称：天原股份 公告编号： 2025-037 债券代码:524174.SZ 债券简称：25 天原 K1 宜宾天原集团股份有限公司 关于控股股东增持公司股份进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 宜宾天原集团股份有限公司（简称：公司）控股股东宜宾发展 控股集团有限公司（简称：宜发展）计划自本增持计划公告披露之 日（2025 年 2 月 11 日）起六个月内增持公司股份，拟增持金额不低 于人民币 1.5 亿元，不高于人民币 3 亿元。 目前增持计划时间已过半，截至 2025 年 5 月 9 日，宜发展通过 深圳证券交易所交易系统以集中竞价方式累计增持公司股份 8,150,420 股，占公司总股本的 0.63%，增持金额合计 37,090,337.93 元。 一、基本情况 公司于 2025 年 2 月 11 日披露了《关于控股股东增持公司股份计 划的公告》（公告编号：2025-011 号），公司控股股东宜发展计划 自本增持计划公告披露之日（2025 年 2 月 11 日）起六个月内增持公 司股份，拟增持金额 ...

宜宾发展控股集团有限公司 您可使用手机"扫一扣"或近入"注册会计师行业统一照管平台（http://acc.mof.gov.cn) "进行查验 报告编码:京25KRFKJ9Q/ 审计报告 天职业字[2025]25505 号 宜宾发展控股集团有限公司: 审计报告 天 职 业 字 [2025]25505 号 | | 目 | 求 | | | --- | --- | --- | --- | | 审 计 报 告 | | | T | | 2024年度财务报表- | | | | | 2024 年 度 财 务 报 表 附 注 - | | | -16 | 一、审计意见 我们审计了宜宾发展控股集团有限公司(以下简称"宜发展集团")财务报表,包括 2024 年 12 月 31 日的合并及母公司资产负债表,2024 年度的合并及母公司利润表、合并及母公司 现金流量表、合并及母公司所有者权益变动表,以及财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了 宜发展集团 2024 年 12 月 31 日的合并及母公司财务状况以及 2024 年度的合并及母公司经营 成果和合并现金流量。 二、形成审计意见 ...

Core Viewpoint - The "climax needle" concept has led to significant stock price fluctuations in related companies, highlighting the volatility and speculative nature of the medical beauty industry [1][4]. Group 1: Market Reaction - On April 28, after the opening of A-shares, stocks related to the "climax needle" concept experienced a collective decline, with Bawei Co. (837023) dropping over 9%, Demei Chemical (002054.SZ) down more than 7%, and Tianyuan Co. (002386.SZ) falling over 5% [1]. - Prior to the decline, these stocks had surged due to speculation surrounding the "climax needle," with some reaching their daily limit [1]. Group 2: Product Details - The "climax needle" is marketed as an injection of collagen at sensitive points within the female vagina, with prices ranging from thousands to tens of thousands of yuan [1]. - A specific product developed by Yuanxiang Biotechnology is priced at 9,800 yuan per injection and is classified as a "platelet-rich plasma preparation device" (PRP), which is a strictly regulated Class III medical device [3]. Group 3: Medical and Regulatory Insights - PRP technology involves extracting a patient's blood, processing it to concentrate platelets, and utilizing growth factors for tissue repair and regeneration [3]. - While PRP has been increasingly applied in the medical beauty sector, the National Medical Products Administration has not yet issued clear approvals for its use in facial injections, despite existing clinical literature [3][4]. - Experts have criticized the "climax needle" as lacking scientific support and warned of potential risks associated with its use, indicating a need for regulatory scrutiny in the medical beauty industry [1][4].

Financial Performance - Company reported total revenue of 3.141 billion yuan for Q1 2025, an increase of 4.42% year-on-year [1] - Net profit attributable to shareholders reached 11.3683 million yuan, up 73.46% compared to the same period last year [1] - Gross margin improved to 6.14%, reflecting a year-on-year increase of 52.56%, while net margin rose to 0.18%, a significant increase of 292.04% [1] Cost and Expenses - Total selling, administrative, and financial expenses amounted to 176 million yuan, accounting for 5.6% of revenue, which is a slight increase of 1.76% year-on-year [1] - The company’s operating cash flow per share was -0.15 yuan, showing a year-on-year increase of 4.33% [1] Balance Sheet and Debt - Cash and cash equivalents decreased by 14.02% to 3.267 billion yuan [1] - Accounts receivable increased by 73.99% to 681 million yuan, indicating potential liquidity concerns [1] - Interest-bearing liabilities rose by 10.90% to 8.253 billion yuan, with a debt-to-asset ratio of 40.21% [3] Shareholder Returns - The company has cumulatively raised 4.226 billion yuan since its listing, with total dividends amounting to 699 million yuan, resulting in a dividend-to-financing ratio of 0.17 [3]

Group 1 - The titanium dioxide concept sector rose by 1.62%, ranking third among concept sectors, with 11 stocks increasing in value, including Tianyuan Co., which hit the daily limit, and Zhenhua Co., Kuncai Technology, and Guocheng Mining, which rose by 7.31%, 4.03%, and 3.62% respectively [1] - The main capital inflow into the titanium dioxide concept sector was 144 million yuan, with Zhenhua Co. leading the inflow at 122 million yuan, followed by Tianyuan Co., Kuncai Technology, and Guocheng Mining with inflows of 51.42 million yuan, 21.03 million yuan, and 6.29 million yuan respectively [2][3] - The top three stocks by net capital inflow ratio were Kuncai Technology, Zhenhua Co., and Tianyuan Co., with net inflow ratios of 17.37%, 16.29%, and 9.97% respectively [3] Group 2 - The stocks with the largest declines included Daon Co., Luban Chemical, and Donghua Technology, which fell by 2.97%, 2.80%, and 1.76% respectively [1][4] - The trading volume and turnover rates for the leading stocks in the titanium dioxide sector showed significant activity, with Zhenhua Co. having a turnover rate of 6.65% and Tianyuan Co. at 8.44% [3]